AUR-101 by Aurigene Oncology for Psoriatic Arthritis: Likelihood of Approval

AUR-101 is under clinical development by Aurigene Oncology and currently in Phase II for Psoriatic Arthritis.

Highlights from the EHA Congress 2023 meeting: allogeneic cell therapy updates – Pharmaceutical Technology

For blood cancers, GlobalData’s Pharma Intelligence Center (PIC) lists 58 alloCAR-T products and 129 clinical trial programmes. Credit: Mesa Studios via Shutterstock. The development of

July 18, 2023

Eli Lilly targets Scorpion Therapeutics to expand reach in oncology – Pharmaceutical Technology

Eli Lilly has announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor program. Credit: Michael Vi via Shutterstock. Eli Lilly will buy Boston biotech Scorpion Therapeutics’

January 13, 2025

Study may facilitate the development of new personalized treatments for schizophrenia An International Study Publi…

An international study led by the Hospital del Mar Medical Research Institute, in collaboration with researchers from the Neuropsychopharmacology Group at the University of the

May 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.